Abstract
About 10-25% of breast cancer patients achieve a pathologically confirmed complete response after neoadjuvant chemotherapy. Tissue samples of pretreatment core biopsies are a valuable resource for translational research aiming towards predictive biomarkers for selecting patients who are likely to benefit from neoadjuvant therapy. The German Breast Group (GBG) and the AGO-B Group (AGO = Working Group Gynecological Oncology) have extensive experience in conducting neoadjuvant clinical trials. Technologies as immunohistochemistry on tissue microarrays and standardized reverse transcription-polymerase chain reaction (RT-PCR) approaches on formalin-fixed paraffin-embedded samples allow high-throughput investigation of protein and mRNA biomarkers. With these approaches, we could demonstrate that molecular tumor subtypes and immunological infiltrates are valuable and independent predictors of therapy response. New biomarkers such as poly(ADP-ribose) polymerase (PARP) might be useful for the prediction of response to conventional and new targeted therapies. This review summarizes current research projects focusing on biomarker discovery in the neoadjuvant setting.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 265-272 |
| Number of pages | 8 |
| Journal | Breast Care |
| Volume | 6 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2011 |
Keywords
- Breast cancer
- Chemotherapy
- Lymphocytes
- Neoadjuvant
- PARP
ASJC Scopus subject areas
- Surgery
- Oncology